Albain KS et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst 2021;113(4):390-9. Abstract

Bartlett JMS et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen — To Offer More? (aTTom) trial. Ann Oncol 2019;30(11):1776-83. Abstract

Buus R et al. Molecular drivers of Onco type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC study. J Clin Oncol 2021;39(2):126-35. Abstract

Cardoso F et al. MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. ASCO 2020;Abstract 506.

Garcia-Murillas I et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 2019;5(10):1473-8. Abstract

Goss PE et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375(3):209-19. Abstract

Kalinsky K et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). San Antonio Breast Cancer Symposium 2020;Abstract GS3-00.

Noordhoek I et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR + early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res 2021;27(1):311-9. Abstract

Pan H et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377(19):1836-46. Abstract

Sestak I et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol 2018;4(4):545-53. Abstract

Sgroi DC et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013;105(14):1036-42. Abstract

Sparano JA et al. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. ASCO 2019;Abstract 503.